Clinical trials: Pain Syndrome
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Chronic Refractory Pain Associated With Failed Back Surgery Syndrome, Epidural Fibrosis, Peripheral Causalgia, Complex Regional Pain Syndrome
Restore Claims Characterization Study
The purpose of this study is to characterize the pain coverage capability of the RESTORE spinal cord stimulation (SCS) and assess health outcomes.
- Trial name
- NCT00200122
- Testing
- Spinal Cord Stimulation
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- MedtronicNeuro
Acute Coronary Syndrome
Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain
The purpose of this study is to evaluate if the implementation of quantitative pretest probability assessment will significantly reduce the unnecessary use of the intra-emergency department chest pain center.
- Trial name
- NCT00243516
- Testing
- PREtest Consult
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- PREtest Consult
Pain, Intractable
OPTIONS Spinal Cord Stimulation Programming Parameters
The purpose of this study is to evaluate programming options in spinal cord stimulation for the management of chronic, intractable pain of the trunk and limbs.
- Trial name
- NCT02503787
- Testing
- Spinal Cord Stimulation (SCS)
- Where
- 11 sites in United States
- Volunteers
- 64 people
- Sponsor
- MedtronicNeuro
Chronic, Intractable Pain of the Trunk and/or Lower Limbs
Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial
Prospective, multi-center, randomized, single blind study
- Trial name
- DELIVERY (NCT03277378)
- Testing
- lead placement followed by BurstDR stimulation
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 270 people
- Sponsor
- Abbott Medical Devices
Pain
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
The primary aim of this study is to determine if chronic pain subjects on around-the-clock opioids who are receiving 100 to 220 mg oral morphine sulfate equivalent (MSE) can be safely transitioned on to buprenorphine…
- Trial name
- NCT01871285
- Testing
- Buprenorphine, Oxycodone, Morphine sulfate
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- BioDelivery Sciences International